Source disclosure: February 12, 2026
Veritas In Silico Inc. [130A.T]
TOKYO, Feb 12 (Pulse News Wire) – Veritas In Silico Inc. (130A.T) reported losses for the fiscal year ended December 31, 2025, despite advancements in its AI drug discovery platform ibVIS®.
Operating revenue was ¥91.1 million, down from the previous year. Research and development expenses amounted to ¥215.6 million, contributing to an lower operating profit of ¥3.967 billion. Net income fell to a loss of ¥425.7 million compared to a loss of ¥236.4 million in the prior year. The company secured patents for ibVIS® across major regions and made significant improvements to its rule-based AI systems. Collaborative research agreements with partners such as Teijin Limited and Shionogi & Co.
Advanced multiple drug pipelines. Additionally, Veritas In Silico initiated projects aimed at developing mRNA-targeting drugs, including a project targeting acute kidney failure after heart surgery which led to filing a patent application for an antisense oligonucleotide (ASO). For the fiscal year ending December 31, 2026, Veritas In Silico forecasts increased revenues driven by ongoing collaborative research contracts and expects total operating revenue of ¥113 million. However, higher research and development costs are anticipated, leading to projected net losses of -¥567 million. The company plans to hold an annual shareholders' meeting on March 24, 2026, and anticipates submitting its financial report by March 23, 2026.
AI-translated content. 🟡 Confidence: Standard See terms • Original filing